Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of SB204 in acne vulgaris
NCT02798120Phase 3Completed
- Sponsor
- Novan
- Start
- May 2016
- Primary completion
- Apr 2017
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of berdazimer in acne vulgaris, sponsored by Novan. Started May 2016; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02798120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798120.